...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Gastric Tolerability and Prolonged Prostaglandin Inhibition in the Brain with a Nitric Oxide-Releasing Flurbiprofen Derivative,NCX-2216 [3-[4-(2-Fluoro-alpha-methyl-[1,1 '-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl este
【24h】

Gastric Tolerability and Prolonged Prostaglandin Inhibition in the Brain with a Nitric Oxide-Releasing Flurbiprofen Derivative,NCX-2216 [3-[4-(2-Fluoro-alpha-methyl-[1,1 '-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl este

机译:一氧化氮释放氟比洛芬衍生物,NCX-2216 [3- [4-(2-氟-α-甲基-[1,1'-联苯] -4-乙酰氧基]]-胃耐受性和对前列腺素的长期抑制作用。 3-甲氧基苯基] -2-丙酸4-硝基氧丁酯

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

NCX-2216 [3-[4-(2-fluoro-a-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester] is an NO-releasing flurbiprofen derivative that also contains a ferulic acid (antioxidant)moiety.NCX-2216 has been shown to be effective in reducing beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease.The tolerability of this compound in the stomach and its ability to suppress prostaglandin synthesis in the brain are not known.The purpose of this study was to assess the contribution of nitric oxide (NO)and ferulic acid to the pharmacological properties of NCX-2216 versus flurbiprofen;thus,we compared their gastric tolerability and suppression of prostaglandin synthesis,peripherally and centrally.Oral flurbiprofen produced extensive gastric damage and suppressed gastric prostaglandin synthesis.In contrast,while suppressing prostaglandin production,equimolar doses of NCX-2216 did not cause detectable gastric injury.The NO-releasing moiety of NCX-2216 (but not the ferulic acid moiety)was crucial for the gastric safety of this compound.NCX-2216 substantially inhibited prostanoid synthesis despite not being detectable in plasma and despite producing only low amounts of flurbiprofen in plasma and in the brain.Inhibition of brain prostaglandin synthesis by NCX-2216 (22 mg/kg)persisted for a much longer period of time (up to 48 h)than was seen with flurbiprofen (<=12 h).These results demonstrate that a single administration of NCX-2216 can produce prolonged suppression of brain prostaglandin synthesis without causing gastric injury.It is likely that an active metabolite of NCX-2216 contributes to the suppression of cyclooxygenase activity.NCX-2216 may represent an attractive alternative to conventional nonsteroidal anti-inflammatory drugs for long-term treatment of a variety of inflammatory disorders,especially those occurring in the central nervous system.
机译:NCX-2216 [3- [4-(2-氟-α-甲基-[1,1'-联苯] -4-乙酰氧基] -3-甲氧基苯基] -2-丙酸4-硝基氧基丁酯]为NO释放的氟比洛芬衍生物,其中还含有阿魏酸(抗氧化剂)部分。NCX-2216在减少阿尔茨海默氏病转基因小鼠模型中的β-淀粉样蛋白沉积方面显示出有效作用。该化合物在胃中的耐受性及其能力抑制脑中前列腺素合成的方法尚不清楚。本研究的目的是评估一氧化氮(NO)和阿魏酸对氟比洛芬对NCX-2216药理特性的影响;因此,我们比较了它们对胃耐受性和抑制作用口服氟比洛芬产生广泛的胃损伤并抑制胃前列腺素的合成。相反,在抑制前列腺素产生的同时,等剂量的NCX-2216不会引起可检测的胃损伤。NCX-的NO释放部分2216(但不是阿魏酸部分)对于该化合物的胃安全性至关重要.NCX-2216尽管在血浆中无法检测到,并且在血浆和大脑中仅产生少量的氟比洛芬,但实际上抑制了前列腺素的合成。与氟比洛芬(<= 12 h)相比,NCX-2216(22 mg / kg)持续合成前列腺素的时间更长(长达48小时)。这些结果表明,单次使用NCX-2216可以产生对脑前列腺素合成的长期抑制作用而不会引起胃损伤。NCX-2216的活性代谢产物可能有助于抑制环氧合酶活性。NCX-2216可以长期替代常规非甾体类抗炎药治疗多种炎性疾病,尤其是中枢神经系统中发生的疾病。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号